<DOC>
	<DOCNO>NCT01331642</DOCNO>
	<brief_summary>Gaucher disease autosomal recessive hereditary lysosomal storage disorder . Occurrence disease due hereditary deficiency Glucocerebrosidase , lysosomal enzyme divide Glucocerebroside Glucose Ceramides .</brief_summary>
	<brief_title>Biomarker Gaucher Disease</brief_title>
	<detailed_description>The unmetabolised Glucocerebrosides store throughout whole reticulo-endothelial system . Accumulation Glycolipid-enriched Macrophages establish pathoanatomical phenomenon , so-called Gaucher cell , verify light microscopy . Activation marker Macrophages , like enzyme Chitotriosidase CCL18 , parameter follow course Gaucher dis-ease . Gaucher disease frequently inherit Sphingolipidosis general population , Ahskenazi Jews , prevalence much high ( 1:450 ) . The gene code Glucocerebrosidase long arm chromosome 1 cover 11 exon . So far , 200 different mutation Gaucher patient describe , mostly missense mutation . In addition frame-shift- splice-site-mutations detect , well insertion deletion . More frequent mutation N370S , L444P , IVS2+1G &gt; A , c.84insG , R463C R496H [ Sidransky E. 2004 ] . The clinical appearance heterogeneous . The classical phenotype characterize visceral organ ( Hepatosplenomegaly ) skeleton system ( Bone marrow infiltrate bone infarct pathological fracture ) affection . Moreover , consecutive blood cell count change , Anemia Thrombocytopenia reported.A serious distinction lie appearance neurological manifestation ( myoclonus epilepsy , hydrocephalus , ocular movement disturbance ) . There discussion whether classification typical three disease type ( type1 : non-neuronopathic progress form , type2 : acute neuronopathic progress form , type3 : chronic neuronopathic progress form ) still up-to-date , since sufficiently reflect reality clinical presentation . A clear genotype-phenotype relationship exist . The DNA mutation detect patient pronounced difference disease progression . The exception mutation N370S , far detected connection visceral progress form ( type1 ) [ Koprivica et al . 2000 ] . At least outcome non-neuronopathic disorder case could improve introduction general availability enzyme therapy . Under kind therapy reduction liver spleen size well normalization haemogram parameter . New method , like mass-spectrometry give good chance characterize blood ( plasma ) affect patent specific metabolic alteration allow diagnose future disease earlier , high sensitivity specificity . The development new bio-chemical marker plasma affected patient goal study .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Lysosomal Storage Diseases</mesh_term>
	<mesh_term>Sphingolipidoses</mesh_term>
	<criteria>Informed consent obtain patient parent study related procedure . Patients first day life The patient diagnosis Gaucher Disease base biochemical and/or genetic criterion highgrade suspicion Gaucher disease Highgrade suspicion present , one inclusion criterion valid : Positive family anamnesis Gaucher disease Splenomegaly without identifiable cause Hepatomegaly without identifiable cause Anemia thrombocytopenia without identifiable cause CNS involvement without identifiable cause No Informed consent patient parent study related procedure No diagnosis Gaucher disease valid criterion profound suspicion Gaucher disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Lipidoses</keyword>
	<keyword>Lipid Metabolism , Inborn Errors</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
</DOC>